RxDoctor Payments Data

Steven Grieper, DO

Hospitalist · Daytona, FLNPI 1508830761

Payments from drug & device makers

$1,581in general payments, 2019–2025

Across 20 payments — averaging $79.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$538
  • CSL Behring$249
  • Pacira Pharmaceuticals Incorporated$122
  • Amgen$120
  • AbbVie$116
  • E.r. Squibb & Sons, L.L.C.$115
  • plus $321 from 5 others

What the payments were for

  • Food & beverage$1,581100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,581 in reported general payments places this provider in the 90th percentile of 1,570 hospitalist providers in Florida.

See all hospitalist providers in Florida

Medicare billing

Part B allowed, 2024
$99,687
Medicare patients
291
Services billed
899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban37$22,707
EntrestoSacubitril/Valsartan14$9,221
SymbicortBudesonide/Formoterol Fumarate11$2,904
Pantoprazole Sodium97$646
Albuterol Sulfate HfaAlbuterol Sulfate24$638
Atorvastatin Calcium49$387
Ondansetron OdtOndansetron15$319
Prednisone25$308
Nitroglycerin20$298
Cefdinir17$276
ClopidogrelClopidogrel Bisulfate32$267
Carvedilol25$244
CefuroximeCefuroxime Axetil15$231
Metoprolol Succinate25$198
Levothyroxine Sodium18$172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSymbicort$538$2,90411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,570 hospitalist providers in Florida.

Other hospitalist in Daytona

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →